Skip to content

Small Sample,Unicentric,Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss

Small Sample,Unicentric,Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05849519
Enrollment
36
Registered
2023-05-09
Start date
2022-02-16
Completion date
2024-02-16
Last updated
2023-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden Sensorineural Hearing Loss

Keywords

Sudden Sensorineural Hearing Loss, Coenzyme I

Brief summary

Sudden sensorineural hearing loss is one of the most common emergencies in otorhinolaryngology, and its incidence is increasing year by year and tends to be younger. At present, the pathogenesis of sudden deafness is not clear and the individual treatment effects vary significantly. In order to break through this specific treatment bottleneck, this project pioneered the clinical application of the co-regulator nicotinamide adenine dinucleotide (NAD+) in the treatment of sudden deafness. Therefore, this project intends to use pure tone audiometry, speech audiometry, tinnitus disability scale THI, tinnitus subjective visual analog score method VAS, ear fullness subjective visual analog score method VAS for data analysis, and explore the safety of coenzyme I for injection on sudden deafness and efficacy assessment.

Detailed description

The recruited participants were patients with sudden hearing deafness, and the basic demographic data, including name, gender, age, medical history, etc., were collected. According to the inclusion and exclusion criteria, the patients were randomly divided into the experimental group and the control group. The experimental group was given conventional treatment + coenzyme I for injection, and the control group was given conventional treatment for 14 days. Baseline data were collected before treatment, and post-treatment data were collected on 3d, 7d, 14d,1m and 3m of treatment. Baseline data and post-treatment data included pure tone audiometry, speech audiometry, tinnitus THI scale, tinnitus VAS scale, tinnitus Stupid VAS scale.

Interventions

DRUGCoenzyme I for Injection + conventional treatment

The intervention group used Coenzyme I for injection and conventional treatment for 7 consecutive days

DRUGConventional treatment

The control group was treated with conventional treatment

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥18yrs.the 2019 American Sudden Deafness Guidelines are for patients with sudden deafness over 18 years of age; 2. Patients diagnosed with sudden deafness, i.e. unexplained sensorineural hearing loss occurring within 72 hours, with hearing threshold ≥30 in at least 3 consecutive frequencies, refer to the 2019 American Sudden Deafness Guidelines; 3. Unilateral sudden deafness; 4. Within 1 week of the onset of sudden deafness, no treatment in another hospital/our hospital; 5. No major neurological disease, serious systemic disease, family genetic history, major mental illness; 6. Informed and agreed to join the experiment, no plan to move out or go out within 1 month.

Exclusion criteria

1. Other diseases such as acoustic neuroma diagnosed by imaging; 2. Those who cannot tolerate NAD+; 3. pregnant; 4. Any other circumstances that the investigator believes should be excluded from this study; 5. Do not agree to join the experiment, plan to move out or go out within 1 month.

Design outcomes

Primary

MeasureTime frameDescription
Pure Tone Average(PTA)Baseline, before treatmentPure tone audiometry is the most basic and preferred hearing test method, which can qualitatively and quantitatively diagnose hearing loss, can reflect the entire auditory conduction pathway from the external ear to the auditory center, and is currently one of the subjective behavioral hearing tests that can accurately reflect hearing acuity. Includes pure tone air conduction hearing threshold test and pure tone bone hearing threshold test.

Secondary

MeasureTime frameDescription
Speech Recognition RateBaseline, before treatmentThe speech recognition rate is the percentage (%) of speech which can be heard correctly in the audiometric vocabulary list, and the curve is drawn according to the (%) understood by different sound intensity levels, that is, the speech audiogram.
Tinnitus Handicap InventoryBaseline, before treatmentThe Tinnitus Handicap Inventory (THI) is a tool to measure the impact of tinnitus on daily life. Yes (always has): 4 points; Sometimes (intermittent presence): 2 points.None: 0 points; None:0 points. Divide tinnitus into grade 5 I (mild), THI score 1\ 16 divide; Grade 2 (mild), THI score 18\ 36 points; Level 3 (moderate), THI score 38\ 56 points; Level 4 (severe), THI score 58\ 76 points; Level 5 (catastrophic), THI score 78\ 100 points.
Visual Analogue Scale of TinnitusBaseline, before treatmentVAS (Visual Analogue Scale) is a tool to detect changes in the subjective loudness of tinnitus. 0 represents no tinnitus loudness at all, 10 represents the presence of extremely severe loudness, and the middle represents different degrees of tinnitus loudness.
Severity of ear fullnessBaseline, before treatmentVisual Analogue Scale(VAS).0 represents no ear stuffiness at all, 10 represents the presence of extremely severe ear stuffiness, and the middle represents different degrees of ear stuffiness.

Countries

China

Contacts

Primary ContactMinqian Gao, B.Sc
gaomq6@mail.sysu.edu.cn13660778861

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026